TNF Pharmaceuticals, Inc.
TNFA
$0.22
$0.02814.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.22M | 6.11M | 6.92M | 9.02M | 8.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.66M | 11.38M | 13.40M | 17.32M | 16.36M |
| Operating Income | -8.66M | -11.38M | -13.40M | -17.32M | -16.36M |
| Income Before Tax | -23.36M | -23.66M | -17.69M | -12.29M | -4.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.36 | -23.66 | -17.69 | -12.29 | -4.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.36M | -23.66M | -17.69M | -12.29M | -4.00M |
| EBIT | -8.66M | -11.38M | -13.40M | -17.32M | -16.36M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -11.88 | -13.51 | -10.56 | -9.23 | -5.29 |
| Normalized Basic EPS | -6.46 | -6.84 | -4.62 | -3.84 | -1.66 |
| EPS Diluted | -11.88 | -13.51 | -12.03 | -10.71 | -6.77 |
| Normalized Diluted EPS | -6.46 | -6.84 | -5.97 | -5.19 | -3.01 |
| Average Basic Shares Outstanding | 9.71M | 8.63M | 7.78M | 6.92M | 6.17M |
| Average Diluted Shares Outstanding | 9.71M | 8.63M | 14.04M | 13.17M | 12.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -10.66% | -10.93% | -14.62% | -21.04% | -36.30% |